Pazopanib (CAS 444731-52-6) Tyrosine Kinase Inhibitor API

Pazopanib (CAS 444731-52-6) is a high-purity tyrosine kinase inhibitor API with a targeted molecular mechanism, blocking vascular endothelial growth factor receptors (VEGFR) and platelet-derived growth factor receptors (PDGFR) to inhibit tumor angiogenesis and cell proliferation. Its refined crystalline form ensures consistent bioactivity and low impurity profiles, making it a reliable active ingredient for oncology pharmaceutical R&D.

Tailored for pharmaceutical manufacturers and cancer research institutions, this product adheres to strict international quality and regulatory standards. It addresses the core demand for targeted antitumor raw materials, supporting the development of formulations for solid tumor research. Its stable chemical structure guarantees extended shelf life, facilitating flexible formulation design for oral preparations and clinical trial applications.